Positive phase2 results reported for RPC1063 in relapsing MS
Positive phase2 results reported for RPC1063 in relapsing MS
Receptos, Inc. announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis (RMS) met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development..... Read More - http://www.ms-uk.org/RPC1063
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post